Home/Pipeline/AD-214

AD-214

Fibrotic diseases (IPF, kidney fibrosis)

Phase 2Active

Key Facts

Indication
Fibrotic diseases (IPF, kidney fibrosis)
Phase
Phase 2
Status
Active
Company

About AdAlta

Australian biotech delivering CAR‑T and i‑body therapies for solid tumours, fibrosis and malaria.

View full company profile